Graves Ophthalmopathy: Pathophysiology, Diagnosis, and Management.
DOI:
https://doi.org/10.55175/cdk.v51i4.1059Keywords:
Inflammatory, orbital tissue, Graves ophthalmopathy, autoimmune thyroid diseaseAbstract
Graves ophthalmopathy (OG) is an inflammatory disorder of orbital tissue associated with autoimmune thyroid disease. The complex interaction of endogenous and exogenous or environmental (modifiable) factors are known to trigger the occurrence of OG. The symptoms can have a negative impact on the patient’s quality of life, both physical and psychosocial, and become a burden on public health costs. Early diagnosis, management, and immediate referral to related specialists are very important to prevent the progression of the disease.
Downloads
References
Subekti I, Soewondo P, Soebardi S, Darmowidjojo B, Harbuwono DS, Purnamasari D, et al. Practical guidelines management of Graves ophthalmopathy [Internet]. Acta Medica Indonesiana 2023;51(4):36471.
Korn BS. 2021-2022 Basic and clinical science course, section 7: Oculofacial plastic and orbital surgery. In: Rapuano CJ, Stout J, McCannel C, editors. American Academy of Ophthalmology; 2021.
Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, et al. The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur J Endocrinol 2021;185:43–67.
Burch HB, Perros P, Bednarczuk T, Cooper DS, Dolman PJ, Leung AM, et al. Management of thyroid eye disease: A consensus statement by the American Thyroid Association and the European Thyroid Association. Eur Thyroid J. 2022;11(6):e220189. DOI: 10.1530/ETJ-22-0189.
Irawati Y, Juhrie DM, Paramita C, Siswoyo D, Suharko H, Pramono LA. Sight-threatening condition in severe thyroid eye disease: How we should manage. Acta Med Indones. 2022 Jan;54(1):124-30.
Bartalena L, Piantanida E, Gallo D, Lai A, Tanda ML. Epidemiology, natural history, risk factors, and prevention of Graves’ orbitopathy. Front Endocrinol (Lausanne). 2020 Nov 30:11:615993. DOI: 10.3389/fendo.2020.615993.
Subekti I. Oftalmopati Graves: Perbandingan karakterisitik klinis, kadar hormon, dan kadar antibodi reseptor TSH. eJKI. 2018;6:33–8.
Hartomuljono C, Nusanti S. Evaluasi 97 pasien oftalmopati Graves’ selama 3 tahun menggunakan algoritma eugogo dan konsensus nasional [Internet]. [cited 2023 Sept 11]. Available from: https://perdami.or.id/ophthalmologica/journal/article/view/100305.
Bartalena L, Tanda ML. Current concepts regarding Graves’ orbitopathy. J Intern Med 2022;292:692–716.
Yu CY, Ford RL, Wester ST, Shriver EM. Update on thyroid eye disease: Regional variations in prevalence, diagnosis, and management. Indian J Ophthalmol. 2022;70:2335–45.
Rashad R, Pinto R, Li E, Li E, Sohrab M, Distefano AG. Thyroid eye disease. Life 2022;12(12):2084.
Yoon J, Kikkawa D. Thyroid eye disease: From pathogenesis to targeted therapies. Taiwan J Ophthalmol. 2022;12:3–11.
Pelewicz-Sowa M, Miśkiewicz P. Dysthyroid optic neuropathy: Emerging treatment strategies. J Endocrinol Investig. 2023;46:1305–16.
Djunaedi LA, Iskandar F, Kuswidyati C. Selenium sebagai terapi oftalmopati Graves derajat ringan tinjauan pustaka. J Indon Med Assoc. 2019;69:290–95.
Huang X, Tang W, Shen Y, He L, Tong F, Liu S, et al. The significance of ophthalmological features in diagnosis of thyroid-associated ophthalmopathy. Biomed Eng Online 2023;22:7. DOI: 10.1186/s12938-023-01073-3.
Munandar MA. Hubungan clinical activity score dengan NOSPECS pada pasien thyroid-associated orbitopathy [Thesis]. 2022 [cited 2023 Sep 11]. Available from: https://perpustakaanrsmcicendo.com/wp-content/uploads/2022/01/Tesis-dr-Arief.pdf.
Hall AJH, Topliss DJ. Medical and surgical treatment of thyroid eye disease. Intern Med J 2022;52:14–20
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Meri Estivo Sihombing, Nikolaus Lizu Tallo
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
